Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

42.97
-0.9500-2.16%
Post-market: 42.970.00000.00%16:08 EDT
Volume:671.23K
Turnover:29.31M
Market Cap:2.66B
PE:49.82
High:45.43
Open:44.15
Low:42.85
Close:43.92
Loading ...

Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study

MT Newswires Live
·
09 May

Protagonist announces icotrokinra data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
09 May

Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities

TIPRANKS
·
07 May

Protagonist Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Protagonist Therapeutics reports Q1 EPS (19c), consensus 11c

TIPRANKS
·
07 May

Protagonist Therapeutics Q1 EPS $(0.19) Misses $0.18 Estimate, Sales $28.32M Miss $30.44M Estimate

Benzinga
·
07 May

Protagonist Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
06 May

Protagonist Therapeutics Reports Granting of Inducement Award

ACCESS Newswire
·
17 Apr

Protagonist Therapeutics’ Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects

TIPRANKS
·
11 Apr

Protagonist Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Apr

Protagonist Therapeutics: Promising Clinical Data and Strategic Expansion Drive Buy Rating

TIPRANKS
·
11 Apr

Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song

TIPRANKS
·
10 Apr

Protagonist Therapeutics on Pace for Record Losing Streak -- Data Talk

Dow Jones
·
02 Apr

Protagonist Therapeutics Price Target Maintained With a $70.00/Share by Wedbush

Dow Jones
·
28 Mar

BRIEF-Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA

Reuters
·
21 Mar

Protagonist Therapeutics Inc - Transition to Takeda of Leadership for Nda Preparation Underway

THOMSON REUTERS
·
21 Mar

Protagonist Therapeutics- Takeda to Lead Regulatory Strategy for Rusfertide in Polycythemia Vera Nda

THOMSON REUTERS
·
21 Mar

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Insider Monkey
·
19 Mar

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

ACCESS Newswire
·
18 Mar

Protagonist Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
12 Mar